AB Corporate Bond ETF (NASDAQ:EYEG) Shares Cross Below Fifty Day Moving Average – Should You Sell?

AB Corporate Bond ETF (NASDAQ:EYEG)’s stock price passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $34.68 and traded as low as $34.38. AB Corporate Bond ETF shares last traded at $34.39, with a volume of 23 shares changing hands.

AB Corporate Bond ETF Price Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.07. The stock has a market capitalization of $27.51 million, a price-to-earnings ratio of -20.47 and a beta of 0.18. The business’s 50 day simple moving average is $34.68 and its 200-day simple moving average is $35.11.

AB Corporate Bond ETF Cuts Dividend

The firm also recently disclosed a monthly dividend, which was paid on Friday, September 4th. Stockholders of record on Tuesday, September 1st were given a dividend of $0.1284 per share. The ex-dividend date was Tuesday, September 1st. This represents a c) annualized dividend and a dividend yield of 4.5%. AB Corporate Bond ETF’s payout ratio is currently -101.79%.

Institutional Trading of AB Corporate Bond ETF

A hedge fund recently bought a new stake in AB Corporate Bond ETF stock. Kestra Advisory Services LLC purchased a new position in AB Corporate Bond ETF (NASDAQ:EYEG) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 951 shares of the specialty pharmaceutical company’s stock, valued at approximately $34,000. Kestra Advisory Services LLC owned approximately 0.13% of AB Corporate Bond ETF as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 64.16% of the company’s stock.

AB Corporate Bond ETF Company Profile

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.